Single-cell functional assays shed light on LDLR variant pathogenicity in FH. 📊 Highlights the value of functional in vitro testing to classify VUS within ACMG/AMP guidelines—crucial for accurate diagnosis and genetic counseling. 🔗sciencedirect.com/science/articl… European Atherosclerosis Society

In a 119-lesion OCT analysis, only antithrombotic biomarkers (plasminogen & ATIII) correlated with layered plaque. Higher antithrombotic levels → higher layer index, underscoring a key role of endogenous fibrinolysis in plaque healing. 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

Traditional LDL-C formulas struggle in high-TG settings, often leading to major underestimation and misclassification. A new neural network–based model overcomes these limits—fixing the high-TG bias and boosting accuracy. 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

After 1 year of lipid-lowering therapy, patients with severe hypercholesterolemia show normal monocyte responses, no persistent histone activation, and no neutrophil activation—suggesting a reset of trained immunity. 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

Heterozygous deletion of transferrin receptor 1 (TfR1) markedly reduces atherosclerosis in ApoE⁻/⁻ mice, independently of lipid levels, stress and macrophage accumulation. 👉 TfR1 emerges as a potential target for atherosclerosis 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

Poecilobdella manillensis (leech-derived bioactive compounds) ameliorate endothelial injury and inflammation in atherosclerosis through PI3K/AKT and NF-κB pathways. 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

Long-term bisphosphonate use is associated with increased arterial calcification, especially coronary artery calcification, with a clear dose–response relationship. 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

The STATRIP survey highlights physicians’ perspectives on statin therapy. Misconceptions about statin-related adverse effects remain common. Targeted education is needed to optimize dyslipidemia care. doi.org/10.1016/j.athp… European Atherosclerosis Society

Are standard lipid reference ranges reliable during pregnancy? Triglycerides rise 2–3× by the 3rd trimester, older women show more atherogenic profiles, and many are misclassified. ➡️ Population-, age- & trimester-specific ranges are needed. doi.org/10.1016/j.athp… European Atherosclerosis Society

Does inflammation drive restenosis? 🔍 This meta-analysis shows higher pre-procedural CRP is linked to carotid & intracranial restenosis after revascularisation. CRP may be a key risk marker. doi.org/10.1016/j.athp… European Atherosclerosis Society

Real-world use of bempedoic acid was associated with a 21% LDL-C reduction and BA+ezetimibe with a 33% reduction at 3 months. Over 12 months, the proportion of patients achieving LDL-C <70 mg/dL increased from 6–9% at baseline to 18–28%. doi.org/10.1016/j.athp… European Atherosclerosis Society

New research on unstable carotid plaques reveals that abnormal phosphatidylcholine metabolism drives plaque instability by activating ER stress pathways (especially PERK/CHOP). 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

Why do some atherosclerotic plaques become dangerous? This new study shows that G9A, an epigenetic enzyme, promotes vascular calcification by activating BMP2 signaling and pushing smooth muscle cells to change identity. 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

Which metabolic biomarkers drive arterial calcification? A new study using NMR profiling, MR, and large cohorts identifies fatty acid ratios causally linked to lower CAC and a male-specific association for GlycA, with implications for CHD risk. doi.org/10.1016/j.athp…

Beyond lipid regulation, VSMC-derived PCSK9 drives vascular inflammation, phenotypic switching, and plaque progression. PCSK9 inhibition may stabilize plaques beyond LDL lowering. 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

Is there a link between non-steroidal anti-inflammatory drugs and cardiovascular risk in patients with inflammatory arthritis? 🔗doi.org/10.1016/j.athp… European Atherosclerosis Society

HIV is no longer just a chronic infection—it’s a cardiovascular risk factor. This population-based study in Uganda finds higher arterial stiffness and ~2x increased odds among PLWH. Time to integrate CVD screening into HIV care. doi.org/10.1016/j.athp…

Calciprotein particles (CPPs), formed during calcium–phosphate overload, impair autophagic flux in vascular cells via lysosomal dysfunction. A mechanistic link between chronic mineral stress and vascular dysfunction doi.org/10.1016/j.athp… European Atherosclerosis Society

Real-world evidence confirms bempedoic acid delivers ≥20% LDL-C reduction, consistent with RCTs. Effective both with statins and in statin-intolerant patients. No new safety signals observed. doi.org/10.1016/j.athp… European Atherosclerosis Society

PCSK9 inhibition does not alter monocyte subset distribution in high-risk patients, but reshapes monocyte–lipoprotein interactions. An Lp(a)–intermediate monocyte link emerges, while KIV-2 repeats appear to drive inflammation more than Lp(a) levels. doi.org/10.1016/j.athp…